RNA-interference Market growth foreseen by 2023; growing CAGR 20.2% | ALNYLAM PHARMACEUTICALS, BENITEC BIOPHARMA, ISIS PHARMACEUTICALS, RXI PHARMACEUTICALS, FILMTEC CORPORATION, SILENCE THERAPEUTICS

The RNAi market is expected to witness a CAGR of 20.2% during the forecast period. North America dominates the global market due to high incidence of genetic and metabolic disorders.

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/16822
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Increasing Applications in Molecular Diagnostics, Particularly in Cancer
Cancer diagnosis and treatment is currently undergoing a paradigm shift with the incorporation of RNAi techniques in personalized medicines and molecular diagnostics. The availability of high throughput techniques for the identification of altered cellular molecules and metabolites allows the use of RNAi techniques in various cancer diagnosis and targeting approaches. For diagnostics purposes, small interfering RNAs (siRNA) or microRNAs (miRNA) can be utilized, and commercial availability of siRNAs to silence virtually any gene in the human genome is dramatically accelerating the pace of molecular diagnosis and biomedical research. Increasing application of RNAi in molecular diagnosis and its viability as a therapeutic technique is expected to drive the growth of the RNAi market during the forecast period.
Additionally, improving synthetic delivery carriers and chemical modifications to RNA are also fuelling the growth of the global RNAi technology market.

Key Developments in the Market
• November 2017: Arcturus Therapeutics merged with Alcobra Ltd.
• October 2017: Alnylam and Vir Form Strategic alliance to advance RNAi Therapeutics for infectious diseases.
• October 2017: Arcturus Therapeutics announced strategic collaboration with Johnson & Johnson Innovation to discover and develop RNA medicines.

Major Players:
ALNYLAM PHARMACEUTICALS, QUARK PHARMACEUTICALS INC., BENITEC BIOPHARMA LTD, ISIS PHARMACEUTICALS, RXI PHARMACEUTICALS, FILMTEC CORPORATION, SILENCE THERAPEUTICS, MERCK (SIRNA), TEKMIRA PHARMACEUTICALS CORPORATION, QIAGEN, INVITROGEN, and AMBION, amongst others.

Request Discount on this report @ https://marketprognosis.com/discount-request/16822
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Stringent FDA Regulations and Changing Reimbursement Environment
In the recent years, there has been a decline in the FDA drug approval rates. Getting FDA approval for a new drug has become extremely challenging. It had approved less than half the number of new drugs in 2016 (19 so far), when compared to 2015 (45 total) and 2014 (41 total). Hence, despite the large investments, there has been a decline in the number of innovative drugs manufactured. FDA explains manufacturing standards and other complying issues as major reasons for this declining trend. This can impede the growth of the RNAi therapeutics, especially since the miRNAs and siRNAs fall into the relatively new field of genetic medicine, wherein they may require more intensified clinical trials. The highly extensive clinical trials effectively result in low approval rates of drugs. This would mean that the stringent guidelines will be a major restraint for the growth of the market.
Additionally, the unstable and immunogenic nature of RNA is also restraining the growth of the global RNAi technology market.

North America Dominating the Market
North America, especially the United States, holds the largest market share of the RNAi market. There are a large number of companies and research institutes in the country with a huge amount being invested in research on drug discovery using RNAi technology; the recent technological and medical advances are available in North America. Other factors, such as growing population and high incidence of diseases, such as liver disorders and cancers, are fuelling the regional growth of this market.

Enquiry Before Buying@ https://marketprognosis.com/enquiry/16822
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMarkPvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.